BioSpace News Archive

Specialty Pharma Company Selling Ecoza® (econazole nitrate) topical foam, 1%, Recedo® Topical Gel, Neosalus® Cream, Neosalus® Foam, and Neocera® Advanced Cream Is Focused on Patient Outcomes

Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion Myovant to host conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time

First NDA submission for Company’s lead program, KORSUVA™ Injection – NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection

LYNPARZA ® (olaparib) Receives Three New Approvals in Japan Approvals in Three Types of Cancer Are Based on the PAOLA-1, PROfound and POLO Phase 3 Trials

Preclinical safety, long duration of antibody titers and potential for protection demonstrated in preclinical immunogenicity and challenge studies Vaccine candidate is stable at 2°C to 8°C and room temperature for at least 3 months and ongoing Preclinical studies and revised clinical plan to account for evolving regulatory landscape and emergence of new variants

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Maria Fardis, PhD, MBA, President and Chief Executive Officer of Iovance, plans to present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021, at 10:50 a.m. ET. The live and archived webcasts of the presentation and breakout session will be available in th

STRATA Skin Sciences, Inc. announced that it has renewed its existing debt with a lower interest one-year cash secured loan facility with Israel Discount Bank of New York, a multinational commercial bank.

Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has reviewed the position of Institutional Shareholder Services (“ISS”) regarding the Company’s executive compensation approach for the fiscal year ended July 31, 2020. To acknowledge and address the issues within the ISS report, Dr. Elazar Rabbani, the Company’s Chairperson and CEO, has requested the Compensation Commit

Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced the completion of the safety study evaluating the Healight; ultraviolet A light catheter technology.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (“PRV”) to United Therapeutics Corporation (Nasdaq: UTHR), based on an agreed valuation of $105 million